Evidence map›Paper›PMID 10576656›Full record

ArticleBritish journal of cancer1999

Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.

X X Tian, J Y Chan, J C Pang, J Chen, J H He, T S To, S F Leung, H K Ng

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  2. Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  3. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

X X TianDepartment of Anatomical and Cellular Pathology, Sir YK Pao Centre for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, China.
J Y Chan
J C Pang
J Chen
J H He
T S To
S F Leung
H K Ng
Chinese University of Hong Kong · CNPrince of Wales Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNGuangzhou Medical University Cancer Hospital · CNHong Kong Polytechnic University · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene amplification and enhanced expression of the epidermal growth factor receptor (EGFR) represent the major molecular genetic alteration in glioblastomas and it may play an essential role in cell growth and in the carcinogenic process. On the other hand, the nuclear suppressor proteins PML and p53 are also known to play critical roles in cancer development and in suppressing cell growth. Here we report that, in glioblastoma cells with defective EGFR function, the expressions of both promyelocytic leukaemia (PML) and p53 were altered. Cells that were transfected with the antisense-cDNA of EGFR were found to have more cells in G1 and fewer cells in S phase. In addition, the transfected cells were found to be non-responsive to EGF-induced cell growth. Interestingly, the expression of the suppressors p53 and PML were found to be significantly increased by immunohistochemical assay in the antisense-EGFR cells. Moreover, the PML expression in many of the cells was converted from the nuclear dot pattern into fine-granulated staining pattern. In contrast, the expressions of other cell cycle regulated genes and proto-oncogene, including the cyclin-dependent kinase 4 (cdk4), retinoblastoma, p16INK4a and p21H-ras, were not altered. These data indicate that there are specific inductions of PML and p53 proteins which may account for the increase in G1 and growth arrest in antisense-EGFR treated cells. It also indicates that the EGF, p53 and PML transduction pathways were linked and they may constitute an integral part of an altered growth regulatory programme. The interactions and cross-talks of these critical molecules may be very important in regulating cell growth, differentiation and cellular response to treatment in glioblastomas.

Indexed as

Brain NeoplasmsCell DivisionDNA, AntisenseDNA, NeoplasmErbB ReceptorsGene AmplificationGlioblastomaHumansLeukemia, Promyelocytic, AcuteOncogene ProteinsProto-Oncogene MasTumor Cells, CulturedTumor Suppressor Protein p53DNA, AntisenseDNA, NeoplasmErbB ReceptorsMAS1 protein, humanOncogene ProteinsProto-Oncogene MasTumor Suppressor Protein p53

Identifiers

PMID10576656
PMCPMC2362944
OpenAlexW2002294272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.